Airain ltd Reduces Stake in Charles River Laboratories Intl. Inc (CRL)

Airain ltd cut its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 32.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,731 shares of the medical research company’s stock after selling 5,987 shares during the period. Airain ltd’s holdings in Charles River Laboratories Intl. were worth $1,145,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CRL. Envestnet Asset Management Inc. raised its position in shares of Charles River Laboratories Intl. by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock worth $135,000 after buying an additional 526 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Charles River Laboratories Intl. by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock worth $147,000 after buying an additional 43 shares in the last quarter. Tyers Asset Management LLC purchased a new position in shares of Charles River Laboratories Intl. during the fourth quarter worth $188,000. Massmutual Trust Co. FSB ADV purchased a new position in shares of Charles River Laboratories Intl. during the fourth quarter worth $199,000. Finally, Wsfs Capital Management LLC purchased a new position in shares of Charles River Laboratories Intl. during the fourth quarter worth $205,000. 95.32% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) traded up 0.22% during mid-day trading on Friday, hitting $89.60. The stock had a trading volume of 218,973 shares. The firm has a market cap of $4.27 billion, a PE ratio of 26.22 and a beta of 0.99. The firm has a 50 day moving average price of $89.03 and a 200 day moving average price of $82.35. Charles River Laboratories Intl. Inc has a 52-week low of $67.20 and a 52-week high of $92.61.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. The firm had revenue of $445.80 million for the quarter, compared to analysts’ expectations of $437.04 million. Charles River Laboratories Intl. had a return on equity of 25.75% and a net margin of 9.05%. The firm’s revenue for the quarter was up 25.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.98 EPS. Equities analysts predict that Charles River Laboratories Intl. Inc will post $5.10 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Airain ltd Reduces Stake in Charles River Laboratories Intl. Inc (CRL)” was first published by Mideast Time and is the property of of Mideast Time. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.mideasttime.com/airain-ltd-reduces-stake-in-charles-river-laboratories-intl-inc-crl/1708315.html.

CRL has been the topic of a number of research reports. Jefferies Group LLC reissued a “buy” rating and issued a $106.00 price objective on shares of Charles River Laboratories Intl. in a report on Friday, April 21st. Barclays PLC set a $90.00 price objective on Charles River Laboratories Intl. and gave the company a “hold” rating in a report on Saturday, May 13th. Finally, Citigroup Inc reissued a “neutral” rating and issued a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories Intl. in a report on Thursday, May 11th. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $88.06.

In related news, Chairman James C. Foster sold 4,910 shares of the business’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $87.09, for a total value of $427,611.90. Following the transaction, the chairman now owns 381,730 shares in the company, valued at approximately $33,244,865.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman James C. Foster sold 9,717 shares of the business’s stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $87.64, for a total value of $851,597.88. Following the completion of the transaction, the chairman now owns 388,294 shares in the company, valued at approximately $34,030,086.16. The disclosure for this sale can be found here. Insiders sold a total of 73,112 shares of company stock worth $6,484,138 in the last 90 days. 2.30% of the stock is currently owned by insiders.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.